Abstract:Background: Immune checkpoint blockade (ICB) therapies have achieved great promising results in clinics. However, a large proportion of the patients do not respond to these therapies. Therefore, it is essential to develop new immunotherapy for colorectal cancer. Recent studies have revealed the important roles of tumor-infiltrating cytotoxic T lymphocytes (CTL) in enhancing the immunosensitivity of cancer cells to ICB. Here, we identified that IFI35 induced highly proliferative and cytotoxic states of CD8+ T cells, as well as boosted anti-tumor immunotherapy efficacy for CRC.Methods: In this study, we characterized that the expression of IFI35 is associated with the activation and cytotoxicity of CD8+ T cells by analyzing the public TCGA and proteomic databases. Then we engineered IFI35 expressing murine colon cancer cells and tested their roles on anti-tumor immunity in both immunodeficient and immunocompetent mouse models. Flow cytometry and immunohistochemistry were applied to assess the immune microenvironment. Western blot analysis was used to identify the potential down-streaming signaling pathway regulated by IFI35. We further investigated the efficacy of the IFI35 in combination with various immunotherapeutic treatments. Findings: The transcriptional and proteomic analysis of the activation and cytotoxicity of CD8+ T cells in human cancer samples demonstrated that IFI35 expression is associated with increased CD8+ T cell infiltration and predicted a good outcome in colorectal cancer. The number and cytotoxicity of CD8+ T cells were significantly increased in IFI35-overexpressing tumors. Mechanistically, we identified that the IFNg-STAT1-IRF7 signal axis stimulated IFI35 expression, and tumor-secreted IFI35 promoted the proliferation and cytotoxicity of CD8+ T cells by activating the PI3K/mTOR/AKT signaling pathway in vitro. Furthermore, IFI35 sensitized colorectal cancer cells to immune therapy.Interpretation: Our results emphasized that IFI35 induced a robust expansion of activated CD8+ T cells in colorectal cancer. And it may be a promising biomarker for predicting prognosis and immunotherapy in CRC. Funding Information: This work was supported by the Key-Area Research and Development Program of Guangdong Province (No.2019B020229002), Science and Technology Planning Project of Guangzhou (No. 201902020009, SL2023A04J01608).Declaration of Interests: Authors declare that they have no competing interests.Ethics Approval Statement: All experiments were approved by the Research Ethical Committee of the Sixth Affiliated Hospital of Sun Yet-sen University and in accordance with the National Institutes of Health Guide for the Care and Use of Laboratory animals.

Interferon gamma induces higher neutrophil extracellular traps leading to tumor-killing activity in microsatellite stable colorectal cancer

Intratumoral Injection of Interferon Gamma Promotes the Efficacy of Anti-Pd1 Treatment in Colorectal Cancer

Intratumoral injection of interferon gamma promotes the efficacy anti-PD1 treatment in colorectal cancer

Interferon-γ in the tumor microenvironment promotes the expression of B7H4 in colorectal cancer cells, thereby inhibiting cytotoxic T cells

N-glycosylation Regulates Intrinsic IFN-γ Resistance in Colorectal Cancer: Implications for Immunotherapy

Neutrophil Extracellular Traps Blockade in Combination with PD-1 Inhibition in Treatment of Colorectal Cancer Metastasis.

IFNγ signaling integrity in colorectal cancer immunity and immunotherapy

Dysregulation in IFN-γ signaling and response: the barricade to tumor immunotherapy

Inflammation promotes resistance to immune checkpoint inhibitors in high microsatellite instability colorectal cancer

The Roles of Tumor-associated Neutrophils in Colorectal Cancer Treated with Different Combinatorial Immunotherapies

Inhibiting interferon-γ induced cancer intrinsic TNFRSF14 elevation restrains the malignant progression of glioblastoma

Co-inhibition of TGF-β and PD-L1 pathways in a metastatic colorectal cancer mouse model triggers interferon responses, innate cells and T cells, alongside metabolic changes and tumor resistance

Tumor-Secreted IFI35 Promotes Proliferation and Cytotoxic Activity of CD8+ T Cells&nbsp;Through PI3K/Akt/mTOR Signaling Pathway in Colorectal Cancer

Colorectal cancer-specific IFNβ delivery overcomes dysfunctional dsRNA-mediated type I interferon signaling to increase the abscopal effect of radiotherapy

Pan-cancer analysis of IFN-γ with possible immunotherapeutic significance: a verification of single-cell sequencing and bulk omics research

Low-dose IFN-γ induces tumor cell stemness in tumor microenvironment of non-small cell lung cancer

Innate Tumor Killers in Colorectal Cancer.

Low-Dose IFNγ Induces Tumor Cell Stemness in Tumor Microenvironment of Non–Small Cell Lung Cancer

Tumor-Associated Neutrophils in Colorectal Cancer Development, Progression and Immunotherapy

Interferon Gamma in Cancer Immunotherapy

A high interferon gamma signature of CD8+ T cells predicts response to neoadjuvant immunotherapy plus chemotherapy in gastric cancer